

Item 7.01. Regulation FD Disclosure.

The senior management of Amicus Therapeutics, Inc. (the Company) is using the presentation attached as Exhibit 99.1 to this Current Report in its current meetings with investors and analysts. The presentation includes an update on the Company's estimated 2010 operating expense. As previously announced, the Company's current cash position is expected to be sufficient to fund operations and capital expenditure requirements into the second half of 2011.

The information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits: The Exhibit Index annexed hereto is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Amicus Therapeutics, Inc.

Date: July 15, 2010

By: /s/ Geoffrey P. Gilmore

Geoffrey P. Gilmore

Senior Vice President and General Counsel

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation Materials